PR: Heidelberg Pharma: Promising New Clinical Data on Lead ADC-Candidate HDP-101 to be Presented at ASH Annual Meeting 2024
Ladenburg, Germany, 6 November 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical-stage developer of innovative Antibody Drug Conjugates (ADCs), today announces that new clinical data on its lead Amanitin-based ADC candidate, HDP-101, will be presented at the 66th American Society of Hematology (ASH) Annual Meeting, taking place from 7-10 December 2024 in San Diego, California, USA.
Robert Z. Orlowski, MD, PhD, (Ad Interim) Director of Myeloma and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics, University of Texas, Houston, Texas, and principal investigator at MD Anderson Cancer Center, Houston, Texas, USA, will report the latest developments from the ongoing Phase I/IIa study of HDP-101 for the treatment of relapsed or refractory multiple myeloma.
Currently advancing in its sixth cohort, the study has shown encouraging results, including complete remission in one patient from the fifth cohort who had been previously treated multiple times and had received several courses of HDP-101. In addition, several patients showed promising biological activity and objective improvements, underscoring the potential of HDP-101 as a treatment option for patients with this disease.
66th American Society of Hematology (ASH) Annual Meeting
|
Publication number: |
#3381 |
|
Session: |
654. Multiple Myeloma: Pharmacologic Therapies: Poster II |
|
Presentation title: |
The Anti-BCMA Antibody-Drug Conjugate HDP-101 with a Novel Amanitin Payload Shows Promising Initial First in Human Results in Relapsed Multiple Myeloma |
|
Time & location: |
8 December, 6:00 – 8:00 pm PST, Hall G–H |
|
Presenter: |
Robert Z. Orlowski, MD, PhD, MD Anderson Cancer Center, Houston, Texas, USA |
In October, Robert Z. Orlowski, MD, PhD, along with Heidelberg Pharma's Chief Medical Officer, András Strassz, and another Key Opinion Leader (KOL) in the field of Myeloma, discussed the progress of the dose escalation study of HDP-101 during a R&D webinar.
Robert Z. Orlowski commented, “I would say that this should be considered a great drug for all relapsed or refractory myelomas.”
The recording of the R&D webinar can be found here: Virtual KOL Event on Multiple Myeloma and Updated Clinical Data from the IMS Oral Presentation of HDP-101, an Anti-BCMA ADC